Goldman Sachs’s LumiraDx Limited Warrant LMDXW Stock Holding History

Goldman Sachs’s Portfolio LMDXW Stock Details LMDXW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-215,680	Closed	-$2.16K	–	6078
2024 Q1	$2.16K	Hold	215,680	–	–	﹤0.01%	5491
2023 Q4	$1.85K	Buy	+215,680	New	+$3.19K	﹤0.01%	5556
2021 Q4	–	Sell	-13,182	Closed	-$15K	–	6773
2021 Q3	$15K	Buy	+13,182	New	+$15.3K	﹤0.01%	6166

Other funds holding LMDXW

CVS Health Woonsocket, Rhode Island $225M AUM 8.77% 1-Year Est. Return

Ancora Advisors Cleveland, Ohio $5.19B AUM 23.19% 1-Year Est. Return

Goldman Sachs's LMDXW Position: Q2 2024 in Review

Goldman Sachs sold out of LumiraDx Limited Warrant (LMDXW) in Q2 2024, closing a stake of 215,680 shares — an estimated $2.16K sold.

Goldman Sachs first reported a position in LMDXW in Q3 2021 and held it in 3 quarters. The position peaked at $15K in Q3 2021. 2 funds tracked by Wall St. Rank hold LMDXW as of Q2 2024.

Goldman Sachs reported no remaining LumiraDx Limited Warrant position as of Q2 2024 after selling out during the quarter.
Goldman Sachs sold 215,680 LumiraDx Limited Warrant shares in Q2 2024, an estimated $2.16K.
Goldman Sachs first reported a position in LumiraDx Limited Warrant in Q3 2021 and held it in 3 quarters.
Goldman Sachs's LumiraDx Limited Warrant position peaked at $15K in Q3 2021.
2 funds tracked by Wall St. Rank held LumiraDx Limited Warrant as of Q2 2024.

Based on Goldman Sachs's 13F filing for Q2 2024, filed 13 Aug 2024.